As also observed for ERK phosphorylation (Fig 5C, above), these data agree with clinical reality, where positive outcomes for EGFR and combinatorial BRAF/EGFR inhibition are variable but limited to patients with RAS/RAF‐wild‐type and BRAF‐mutant CRC, respectively. The gene discussed is EPHB2; the disease is colorectal carcinoma.